Infantile Metachromatic Leukodystrophy (MLD): A Rare Case

Varsha Gajbhiye1, Yashwant Lamture2, Punam Uke1

  • 1Pediatrics, Jawaharlal Nehru Medical College, Wardha, IND.

Cureus
|February 2, 2023
PubMed

Insights

Metachromatic leukodystrophy (MLD) is a genetic disorder affecting white matter. Early detection through prenatal and newborn screening is crucial for effective management of this rare lysosomal storage disease.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal sphingolipid storage disease.
  • It primarily affects the white matter of the brain and nervous system.
  • Early symptoms include learning disabilities and behavioral changes, progressing to gait and balance issues.

Observation:

  • A case study of a 2.5-year-old boy with no prenatal screening presented with progressive lower limb weakness and loss of speech.
  • The patient exhibited regression in motor skills and communication abilities.
  • Family history indicated consanguinity, a potential risk factor for genetic disorders.

Findings:

  • Magnetic Resonance Imaging (MRI) revealed periventricular leukodystrophy, a characteristic finding in MLD.
  • Diagnostic indicators include low arylsulfatase A (ARSA) activity, elevated urinary sulphatides, and specific MRI patterns like the trigonid pattern.
  • The observed symptoms and MRI findings strongly suggested MLD.

Implications:

  • This case highlights the importance of prenatal and newborn genetic screening for MLD.
  • Early diagnosis enables timely intervention, potentially improving patient outcomes and management efficacy.
  • Increased awareness and screening can lead to earlier detection of MLD in at-risk populations.